Alnylam Pharmaceuticals, Inc.
ALNY
$304.67
$6.092.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.35B | 2.25B | 2.09B | 2.34B | 2.00B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.35B | 2.25B | 2.09B | 2.34B | 2.00B |
| Cost of Revenue | 328.44M | 323.37M | 306.41M | 304.82M | 321.51M |
| Gross Profit | 2.02B | 1.92B | 1.79B | 2.04B | 1.68B |
| SG&A Expenses | 1.00B | 975.53M | 878.31M | 856.49M | 822.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.46B | 2.43B | 2.28B | 2.24B | 2.18B |
| Operating Income | -115.37M | -176.89M | -188.13M | 102.64M | -175.80M |
| Income Before Tax | -355.38M | -377.38M | -321.10M | -61.70M | -324.74M |
| Income Tax Expenses | -85.68M | -99.22M | 11.16M | 11.24M | 7.33M |
| Earnings from Continuing Operations | -269.70 | -278.16 | -332.26 | -72.94 | -332.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -269.70M | -278.16M | -332.26M | -72.94M | -332.08M |
| EBIT | -115.37M | -176.89M | -188.13M | 102.64M | -175.80M |
| EBITDA | -57.82M | -120.22M | -132.15M | 157.97M | -122.30M |
| EPS Basic | -2.09 | -2.17 | -2.62 | -0.57 | -2.65 |
| Normalized Basic EPS | -1.70 | -1.82 | -1.57 | -0.22 | -1.55 |
| EPS Diluted | -2.10 | -2.17 | -2.62 | -0.60 | -2.68 |
| Normalized Diluted EPS | -1.70 | -1.82 | -1.57 | -0.26 | -1.59 |
| Average Basic Shares Outstanding | 514.12M | 510.58M | 507.07M | 503.70M | 501.63M |
| Average Diluted Shares Outstanding | 514.12M | 510.58M | 507.07M | 509.82M | 507.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |